Skip to content

Complimentary shipping on orders over $120!

AfterPay now available at checkout

Buy One, Get One Free! Ends Dec 2

Dr Charlie Teo

Dr Charlie Teo

Prof. Charlie Teo AM

Prof Charlie Teo has been instrumental in the development, dissemination and acceptance of the concept of keyhole minimally invasive techniques in neurosurgery. His innovative approach to neurosurgical and neurological conditions was demonstrated while in the USA when he established and directed both the Arkansas Pediatric Neuro-oncology Clinic and the University of Arkansas for Medical Sciences’ Movement Disorders Center.

After returning to Australia, he established a fellowship program that attracts over 600 applicants yearly and has trained many of the world’s leading neurosurgeons at distinguished centres such as the Barrow Neurological Institute and Johns Hopkins, Yale, Duke, Stanford, Vanderbilt and Harvard Universities. He currently has academic appointments in Australia, Singapore, USA, Vietnam, Europe and India.

Prof Charlie Teo strongly believes that a surgeon’s responsibility to his patients shouldn’t end after surgery. In keeping with his desire to find cures for recurrent brain tumours he has raised over $50 million that has been used to fund research scientists both in Australia and abroad. He has done this through the Cure for Life Foundation, the Cure Brain Cancer Foundation(Charity of the Year 2016) and currently the Charlie Teo Foundation.

In addition to this, Prof Charlie Teo has over 160 publications in peer-reviewed journals and has authored two books on keyhole approaches to brain tumours and is a guest editor for several journals.

More recently, Prof Charlie Teo has developed and nurtured several game-changing companies: Omniscient Neurotechnology – a data software company that can map the functionality of the brain through “connectomics”; and Cingulum Health – a clinic dedicated to brain health that offers an integrated holistic approach; creating treatment programs that combine personalised and targeted transcranial magnetic stimulation (TMS) with patient specific adjunctive therapies.